Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St set for higher open after Micron revives AI optimism, upbeat economic data
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Moderna (MRNA) PT Raised to $160 at RBC Capital
June 3, 2024 6:40 AM EDTRBC Capital analyst Luca Issi raised the price target on Moderna (NASDAQ: MRNA) to $160.00 (from $135.00) while maintaining a Outperform rating.
The analyst comments "Despite PDUFA date pushed out by a few weeks, MRNA gets approved for RSV. Vaccine efficacy reported on the label (79%)... More
